Summary

  • In December 2025, the Gavi Alliance Board approved a waiver of independent review for reprogramming or a no-cost extension of HSS funding, limited to countries that already had IRC approvals and intended to transition to consolidated funding levers and aligned 2026 grant cycles.
  • The waiver removed a defined review step; it did not erase the prior approval, convert every HSS request into an exception, or establish what any country ultimately received. The useful governance test is whether each covered case can be followed into its Gavi 6.0 instrument.

A grant is easiest to follow at the moment it is approved. The difficult part comes later, when a programme must carry unfinished work into a new funding period, align it with a different budget structure and keep the reasons for its original design visible. Gavi’s transition waiver addressed that administrative seam. Its public record states who could use the exception and why. The next question is whether the path from the old approval to the new grant remains legible after the decision.

Read the decision in the right year

The official Gavi Board Review of Decisions records the waiver under Decision 1 at the Board meeting of 3–4 December 2025. It says the Board approved waiving the independent-review requirement for reprogramming and no-cost extensions of Health Systems Strengthening funding for countries with existing Independent Review Committee approvals, to support their transition into consolidated funding levers and aligned grant cycles in 2026.

That date matters. The July 2026 Board page lists the December 2025 minutes as the previous meeting’s record. A reader who lands on the July page can mistake the embedded minutes for a new July decision. The separate Review of Decisions resolves the chronology and records the Board’s approval. This is a small example of why an exception needs a stable reference that follows it into later documents.

A waiver with boundaries

The approved text contains three substantive boundaries. First, the underlying country funding already had an IRC approval. Second, the change was a reprogramming or a no-cost extension of HSS funding. Third, the purpose was transition to consolidated funding levers and grant cycles aligned in 2026. The decision is not written as a general suspension of IRC review, a waiver for new applications, or permission to enlarge a grant beyond its stated transition purpose.

The IRC’s current public description helps explain what sits behind the review step. The Board appoints the committee as an independent and impartial group of experts. It assesses eligible funding applications against Gavi policies, programme requirements and strategic priorities, and gives recommendations to support funding decisions. Gavi lists technical soundness, strategic alignment, feasibility, sustainability and potential public-health impact among the committee’s considerations. The Board’s waiver therefore concerns a particular point in an existing review chain; it does not make the committee’s broader role disappear.

The distinction is practical. An earlier approval tells a reader that a plan passed an expert assessment at a particular time. It does not, by itself, describe every later change to activities, timing, milestones or funding arrangements. A transition record should make clear what was carried forward and what was altered, without pretending that the original assessment automatically covers changes it did not examine.

The new funding frame

Gavi 6.0 covers 2026–2030. Gavi’s funding-guidance page describes the period’s vaccine and cash support, a consolidated country application, and interim guidance for the period from January 2026 until a new Gavi 6.0 grant starts. The same page retains earlier transition guidance describing HSS and technical-assistance extensions. These documents show that the transition involved a sequence of instruments and time periods, not a single switch on the first day of 2026.

The Board’s wording linked the waiver to that transition. It did not publish a list of countries using it, the value of any changed grant, or the milestones transferred into a successor instrument. Nor does the absence of those details from the public pages reviewed establish that internal case records do not exist. The careful conclusion is narrower: public readers can see the rule and the successor framework, but the public materials reviewed do not connect them case by case.

Make the bridge auditable

For each case relying on the waiver, a compact transition record could identify the prior IRC decision and approved plan; the country’s request and reason for changing it; the check that the case met the waiver’s three boundaries; the authority and date recording that the exception applied; the revised dates, milestones and funding envelope; and the Gavi 6.0 instrument that received the work. A final status could say what was completed, transferred or left open and where the next assurance step sits.

This is not an argument for publishing every sensitive country document. A public register could use case identifiers and aggregated financial fields while retaining the detailed evidence for the country and Gavi’s assurance functions. The aim is to let a later reviewer test continuity: did the new instrument carry the approved purpose, or did the proposal change enough to require a different decision path?

Keep the ordinary review lane visible

The IRC’s published calendar continues to list review windows for new-country and reprogramming applications in 2026 and 2027. That calendar shows a continuing committee function, but it does not identify whether a particular transition case used the waiver. It should not be treated as evidence either that a waived case received another review or that the exception applied outside its stated scope.

A clear public explanation can distinguish two lanes. Existing HSS funding with an earlier IRC approval could use the Board-approved transition exception when the listed conditions were met. New applications, requests outside the HSS reprogramming or no-cost-extension scope, and proposals without a prior IRC approval remain separate questions under the ordinary rules. That distinction protects both administrative continuity and the meaning of independent review.

Sources and limits

The public sources reviewed establish the Board’s decision and its boundaries, the IRC’s stated role, and the public Gavi 6.0 guidance. They do not establish which countries used the waiver, the value or result of any case, or whether internal transition records exist. No conclusion about misuse, service quality or country outcomes follows from the waiver itself.